Hypoxic regulation of angiotensin‐converting enzyme 2 and Mas receptor in human CD34+ cells
CD34+ hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells. Angiotensin‐converting enzyme 2 (ACE2)/angiotensin‐(1–7)/Mas receptor (MasR) pathway stimulates vasoprotective functions of CD34+ cells. This study tes...
Saved in:
Published in | Journal of cellular physiology Vol. 234; no. 11; pp. 20420 - 20431 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.11.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | CD34+ hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells. Angiotensin‐converting enzyme 2 (ACE2)/angiotensin‐(1–7)/Mas receptor (MasR) pathway stimulates vasoprotective functions of CD34+ cells. This study tested if ACE2 and MasR are involved in the hypoxic stimulation of CD34+ cells. Cells were isolated from circulating mononuclear cells derived from healthy subjects (n = 46) and were exposed to normoxia (20% O2) or hypoxia (1% O2). Luciferase reporter assays were carried out in cells transduced with lentivirus carrying ACE2‐ or MasR‐ or a scramble‐3′‐untranslated region gene with a firefly luciferase reporter. Expressions or activities of ACE, angiotensin receptor Type 1 (AT1R), ACE2, and MasR were determined. In vitro observations were verified in HSPCs derived from mice undergoing hindlimb ischemia (HLI). In vitro exposure to hypoxia‐increased proliferation and migration of CD34+ cells in basal conditions or in response to vascular endothelial growth factor (VEGF) or stromal‐derived factor 1α (SDF) compared with normoxia. Expression of ACE2 or MasR was increased relative to normoxia while ACE or AT1R expressions were unaltered. Luciferase activity was increased by hypoxia in cells transfected with the luciferase reporter plasmids coding for the ACE2‐ or MasR promoters relatively to the control. The effects of hypoxia were mimicked by VEGF or SDF under normoxia. Hypoxia‐induced ADAM17‐dependent shedding of functional ACE2 fragments. In mice undergoing HLI, increased expression/activity of ACE2 and MasR were observed in the circulating HSPCs. This study provides compelling evidence for the hypoxic upregulation of ACE2 and MasR in CD34+ cells, which likely contributes to vascular repair.
Bone marrow–derived progenitor cells are recruited to the areas of hypoxia and stimulate vascular regeneration. Exposure to hypoxia upregulates the expression of angiotensin‐converting enzyme 2 (ACE2) and Mas receptor, and ACE2 shedding in progenitor cells. Activation of Mas by angiotensin‐(1–7), a metabolite of ACE2, stimulates vasoreparative functions in progenitor cells and vascular endothelium. |
---|---|
AbstractList | CD34+ hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells. Angiotensin‐converting enzyme 2 (ACE2)/angiotensin‐(1–7)/Mas receptor (MasR) pathway stimulates vasoprotective functions of CD34+ cells. This study tested if ACE2 and MasR are involved in the hypoxic stimulation of CD34+ cells. Cells were isolated from circulating mononuclear cells derived from healthy subjects (n = 46) and were exposed to normoxia (20% O2) or hypoxia (1% O2). Luciferase reporter assays were carried out in cells transduced with lentivirus carrying ACE2‐ or MasR‐ or a scramble‐3′‐untranslated region gene with a firefly luciferase reporter. Expressions or activities of ACE, angiotensin receptor Type 1 (AT1R), ACE2, and MasR were determined. In vitro observations were verified in HSPCs derived from mice undergoing hindlimb ischemia (HLI). In vitro exposure to hypoxia‐increased proliferation and migration of CD34+ cells in basal conditions or in response to vascular endothelial growth factor (VEGF) or stromal‐derived factor 1α (SDF) compared with normoxia. Expression of ACE2 or MasR was increased relative to normoxia while ACE or AT1R expressions were unaltered. Luciferase activity was increased by hypoxia in cells transfected with the luciferase reporter plasmids coding for the ACE2‐ or MasR promoters relatively to the control. The effects of hypoxia were mimicked by VEGF or SDF under normoxia. Hypoxia‐induced ADAM17‐dependent shedding of functional ACE2 fragments. In mice undergoing HLI, increased expression/activity of ACE2 and MasR were observed in the circulating HSPCs. This study provides compelling evidence for the hypoxic upregulation of ACE2 and MasR in CD34+ cells, which likely contributes to vascular repair.
Bone marrow–derived progenitor cells are recruited to the areas of hypoxia and stimulate vascular regeneration. Exposure to hypoxia upregulates the expression of angiotensin‐converting enzyme 2 (ACE2) and Mas receptor, and ACE2 shedding in progenitor cells. Activation of Mas by angiotensin‐(1–7), a metabolite of ACE2, stimulates vasoreparative functions in progenitor cells and vascular endothelium. CD34+ hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells. Angiotensin-converting enzyme 2 (ACE2)/angiotensin-(1-7)/Mas receptor (MasR) pathway stimulates vasoprotective functions of CD34+ cells. This study tested if ACE2 and MasR are involved in the hypoxic stimulation of CD34+ cells. Cells were isolated from circulating mononuclear cells derived from healthy subjects (n = 46) and were exposed to normoxia (20% O2 ) or hypoxia (1% O2 ). Luciferase reporter assays were carried out in cells transduced with lentivirus carrying ACE2- or MasR- or a scramble-3'-untranslated region gene with a firefly luciferase reporter. Expressions or activities of ACE, angiotensin receptor Type 1 (AT1R), ACE2, and MasR were determined. In vitro observations were verified in HSPCs derived from mice undergoing hindlimb ischemia (HLI). In vitro exposure to hypoxia-increased proliferation and migration of CD34+ cells in basal conditions or in response to vascular endothelial growth factor (VEGF) or stromal-derived factor 1α (SDF) compared with normoxia. Expression of ACE2 or MasR was increased relative to normoxia while ACE or AT1R expressions were unaltered. Luciferase activity was increased by hypoxia in cells transfected with the luciferase reporter plasmids coding for the ACE2- or MasR promoters relatively to the control. The effects of hypoxia were mimicked by VEGF or SDF under normoxia. Hypoxia-induced ADAM17-dependent shedding of functional ACE2 fragments. In mice undergoing HLI, increased expression/activity of ACE2 and MasR were observed in the circulating HSPCs. This study provides compelling evidence for the hypoxic upregulation of ACE2 and MasR in CD34+ cells, which likely contributes to vascular repair.CD34+ hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells. Angiotensin-converting enzyme 2 (ACE2)/angiotensin-(1-7)/Mas receptor (MasR) pathway stimulates vasoprotective functions of CD34+ cells. This study tested if ACE2 and MasR are involved in the hypoxic stimulation of CD34+ cells. Cells were isolated from circulating mononuclear cells derived from healthy subjects (n = 46) and were exposed to normoxia (20% O2 ) or hypoxia (1% O2 ). Luciferase reporter assays were carried out in cells transduced with lentivirus carrying ACE2- or MasR- or a scramble-3'-untranslated region gene with a firefly luciferase reporter. Expressions or activities of ACE, angiotensin receptor Type 1 (AT1R), ACE2, and MasR were determined. In vitro observations were verified in HSPCs derived from mice undergoing hindlimb ischemia (HLI). In vitro exposure to hypoxia-increased proliferation and migration of CD34+ cells in basal conditions or in response to vascular endothelial growth factor (VEGF) or stromal-derived factor 1α (SDF) compared with normoxia. Expression of ACE2 or MasR was increased relative to normoxia while ACE or AT1R expressions were unaltered. Luciferase activity was increased by hypoxia in cells transfected with the luciferase reporter plasmids coding for the ACE2- or MasR promoters relatively to the control. The effects of hypoxia were mimicked by VEGF or SDF under normoxia. Hypoxia-induced ADAM17-dependent shedding of functional ACE2 fragments. In mice undergoing HLI, increased expression/activity of ACE2 and MasR were observed in the circulating HSPCs. This study provides compelling evidence for the hypoxic upregulation of ACE2 and MasR in CD34+ cells, which likely contributes to vascular repair. CD34 + hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells. Angiotensin converting enzyme-2 (ACE2)/Angiotensin-(1-7)/Mas receptor (MasR) pathway stimulates vasoprotective functions of CD34 + cells. This study tested if ACE2 and MasR are involved in the hypoxic stimulation of CD34 + cells. Cells were isolated from circulating mononuclear cells (MNCs) derived from healthy subjects (n=46) and were exposed to normoxia (20% O 2 ) or hypoxia (1% O 2 ). Luciferase reporter assays were carried out in cells transduced with Lentivirus carrying ACE2- or MasR- or a scramble-3’-UTR gene with firefly luciferase reporter. Expressions or activities of ACE, AT1R, ACE2 and MasR were determined. In vitro observations were verified in HSPCs derived from mice undergoing hindlimb ischemia (HLI). In vitro exposure to hypoxia increased proliferation and migration of CD34 + cells in basal conditions or in response to VEGF or SDF compared to normoxia. Expression of ACE2 or MasR was increased relative to normoxia while ACE or AT1R expressions were unaltered. Luciferase activity was increased by hypoxia in cells transfected with the luciferase reporter plasmids coding for the ACE2- or MasR promoters relatively to the control. The effects of hypoxia were mimicked by VEGF or SDF under normoxia. Hypoxia induced ADAM-17-dependent shedding of functional ACE2 fragments. In mice undergoing HLI, increased expression/activity of ACE2 and MasR were observed in the circulating HSPCs. This study provides compelling evidence for the hypoxic upregulation of ACE2 and MasR in CD34 + cells, which likely contributes to vascular repair. CD34 + hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells. Angiotensin‐converting enzyme 2 (ACE2)/angiotensin‐(1–7)/Mas receptor (MasR) pathway stimulates vasoprotective functions of CD34 + cells. This study tested if ACE2 and MasR are involved in the hypoxic stimulation of CD34 + cells. Cells were isolated from circulating mononuclear cells derived from healthy subjects ( n = 46) and were exposed to normoxia (20% O 2 ) or hypoxia (1% O 2 ). Luciferase reporter assays were carried out in cells transduced with lentivirus carrying ACE2‐ or MasR‐ or a scramble‐3′‐untranslated region gene with a firefly luciferase reporter. Expressions or activities of ACE, angiotensin receptor Type 1 (AT1R), ACE2, and MasR were determined. In vitro observations were verified in HSPCs derived from mice undergoing hindlimb ischemia (HLI). In vitro exposure to hypoxia‐increased proliferation and migration of CD34 + cells in basal conditions or in response to vascular endothelial growth factor (VEGF) or stromal‐derived factor 1α (SDF) compared with normoxia. Expression of ACE2 or MasR was increased relative to normoxia while ACE or AT1R expressions were unaltered. Luciferase activity was increased by hypoxia in cells transfected with the luciferase reporter plasmids coding for the ACE2‐ or MasR promoters relatively to the control. The effects of hypoxia were mimicked by VEGF or SDF under normoxia. Hypoxia‐induced ADAM17‐dependent shedding of functional ACE2 fragments. In mice undergoing HLI, increased expression/activity of ACE2 and MasR were observed in the circulating HSPCs. This study provides compelling evidence for the hypoxic upregulation of ACE2 and MasR in CD34 + cells, which likely contributes to vascular repair. CD34+ hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells. Angiotensin‐converting enzyme 2 (ACE2)/angiotensin‐(1–7)/Mas receptor (MasR) pathway stimulates vasoprotective functions of CD34+ cells. This study tested if ACE2 and MasR are involved in the hypoxic stimulation of CD34+ cells. Cells were isolated from circulating mononuclear cells derived from healthy subjects (n = 46) and were exposed to normoxia (20% O2) or hypoxia (1% O2). Luciferase reporter assays were carried out in cells transduced with lentivirus carrying ACE2‐ or MasR‐ or a scramble‐3′‐untranslated region gene with a firefly luciferase reporter. Expressions or activities of ACE, angiotensin receptor Type 1 (AT1R), ACE2, and MasR were determined. In vitro observations were verified in HSPCs derived from mice undergoing hindlimb ischemia (HLI). In vitro exposure to hypoxia‐increased proliferation and migration of CD34+ cells in basal conditions or in response to vascular endothelial growth factor (VEGF) or stromal‐derived factor 1α (SDF) compared with normoxia. Expression of ACE2 or MasR was increased relative to normoxia while ACE or AT1R expressions were unaltered. Luciferase activity was increased by hypoxia in cells transfected with the luciferase reporter plasmids coding for the ACE2‐ or MasR promoters relatively to the control. The effects of hypoxia were mimicked by VEGF or SDF under normoxia. Hypoxia‐induced ADAM17‐dependent shedding of functional ACE2 fragments. In mice undergoing HLI, increased expression/activity of ACE2 and MasR were observed in the circulating HSPCs. This study provides compelling evidence for the hypoxic upregulation of ACE2 and MasR in CD34+ cells, which likely contributes to vascular repair. CD34 hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells. Angiotensin-converting enzyme 2 (ACE2)/angiotensin-(1-7)/Mas receptor (MasR) pathway stimulates vasoprotective functions of CD34 cells. This study tested if ACE2 and MasR are involved in the hypoxic stimulation of CD34 cells. Cells were isolated from circulating mononuclear cells derived from healthy subjects (n = 46) and were exposed to normoxia (20% O ) or hypoxia (1% O ). Luciferase reporter assays were carried out in cells transduced with lentivirus carrying ACE2- or MasR- or a scramble-3'-untranslated region gene with a firefly luciferase reporter. Expressions or activities of ACE, angiotensin receptor Type 1 (AT1R), ACE2, and MasR were determined. In vitro observations were verified in HSPCs derived from mice undergoing hindlimb ischemia (HLI). In vitro exposure to hypoxia-increased proliferation and migration of CD34 cells in basal conditions or in response to vascular endothelial growth factor (VEGF) or stromal-derived factor 1α (SDF) compared with normoxia. Expression of ACE2 or MasR was increased relative to normoxia while ACE or AT1R expressions were unaltered. Luciferase activity was increased by hypoxia in cells transfected with the luciferase reporter plasmids coding for the ACE2- or MasR promoters relatively to the control. The effects of hypoxia were mimicked by VEGF or SDF under normoxia. Hypoxia-induced ADAM17-dependent shedding of functional ACE2 fragments. In mice undergoing HLI, increased expression/activity of ACE2 and MasR were observed in the circulating HSPCs. This study provides compelling evidence for the hypoxic upregulation of ACE2 and MasR in CD34 cells, which likely contributes to vascular repair. |
Author | Joshi, Shrinidh Wollenzien, Hannah Leclerc, Estelle Jarajapu, Yagna PR |
Author_xml | – sequence: 1 givenname: Shrinidh surname: Joshi fullname: Joshi, Shrinidh organization: North Dakota State University – sequence: 2 givenname: Hannah surname: Wollenzien fullname: Wollenzien, Hannah organization: North Dakota State University – sequence: 3 givenname: Estelle surname: Leclerc fullname: Leclerc, Estelle organization: North Dakota State University – sequence: 4 givenname: Yagna PR surname: Jarajapu fullname: Jarajapu, Yagna PR email: Yagna.Jarajapu@ndsu.edu organization: North Dakota State University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30989646$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kc1u1DAUhS1URKeFBS-ALLGhQmn9k3jsDRIaoD8qggUskeU4N1OPEjvYSemw4hF4xj4JbmeKoIKN7-J-5_jce_fQjg8eEHpKySElhB2t7HDIpCj5AzSjRM2LUlRsB81yjxaqKuku2ktpRQhRivNHaJcTJZUoxQx9OVkP4cpZHGE5dWZ0wePQYuOXLozgk_PXP37a4C8hjs4vMfjv6x4wy0SD35uUdRaGMUTsPL6YeuPx4g0vX2ILXZceo4et6RI82dZ99Pnd20-Lk-L8w_Hp4vV5YcuS88LKxlZ125CqVbXMD5lTSaGSjWRCSDFX81ryVgmuqACQLYiqqvM0jcm_E-D76NXGd5jqHhoLfoym00N0vYlrHYzTf3e8u9DLcKmFEIQLkQ1ebA1i-DpBGnXv0s0IxkOYkmaMElZVVPKMPr-HrsIUfR4vU4JTwQgrM_Xsz0S_o9xtPgNHG8DGkFKEVls33u4_B3SdpkTf3Fbn2-rb22bFwT3Fnem_2K37N9fB-v-gPlt83Ch-Aftfs-o |
CitedBy_id | crossref_primary_10_1016_j_omtm_2020_05_013 crossref_primary_10_1126_scitranslmed_abc0170 crossref_primary_10_1371_journal_pone_0245055 crossref_primary_10_1097_MOH_0000000000000645 crossref_primary_10_1371_journal_pone_0273524 crossref_primary_10_3389_fphys_2022_960308 crossref_primary_10_3390_ijms22157954 crossref_primary_10_3390_v12111213 crossref_primary_10_3390_cells10071752 crossref_primary_10_3389_fmed_2021_670195 crossref_primary_10_1007_s43440_024_00596_3 crossref_primary_10_1042_CS20200480 crossref_primary_10_1042_CS20201133 crossref_primary_10_1007_s12253_020_00810_6 crossref_primary_10_2174_1570159X19666210806163352 crossref_primary_10_3748_wjg_v30_i31_3705 crossref_primary_10_1016_j_meegid_2022_105207 crossref_primary_10_3390_cells12010012 crossref_primary_10_1097_MPA_0000000000001609 crossref_primary_10_1089_ham_2020_0202 crossref_primary_10_3390_cells9071704 crossref_primary_10_1371_journal_pone_0253458 crossref_primary_10_1113_JP280769 crossref_primary_10_1007_s12015_020_10010_z crossref_primary_10_1016_j_mvr_2021_104232 crossref_primary_10_1016_j_ejcb_2023_151316 crossref_primary_10_1016_j_placenta_2021_12_002 crossref_primary_10_12998_wjcc_v10_i34_12470 crossref_primary_10_3390_ijms222312800 crossref_primary_10_1089_ham_2020_0114 crossref_primary_10_1080_22221751_2021_1932607 crossref_primary_10_1016_j_celrep_2021_109020 crossref_primary_10_3389_fcell_2020_559841 crossref_primary_10_2139_ssrn_3604987 crossref_primary_10_1590_0102_311xen294721 crossref_primary_10_1016_j_jbior_2021_100820 crossref_primary_10_1124_mol_119_117580 crossref_primary_10_1002_path_5555 crossref_primary_10_1126_scisignal_abq1366 crossref_primary_10_3138_ptc_2021_0031 crossref_primary_10_1016_j_jhepr_2023_100936 crossref_primary_10_1159_000520221 crossref_primary_10_1016_j_placenta_2021_01_008 crossref_primary_10_1016_j_ijid_2020_06_080 crossref_primary_10_1038_s41598_021_03710_0 crossref_primary_10_1007_s11357_020_00306_w crossref_primary_10_1152_ajplung_00259_2020 crossref_primary_10_1152_japplphysiol_00109_2020 crossref_primary_10_13105_wjma_v9_i2_108 crossref_primary_10_1016_j_bcp_2023_115805 crossref_primary_10_1042_CS20200492 crossref_primary_10_1007_s12291_021_00967_0 |
Cites_doi | 10.1167/iovs.10‐70911 10.1093/eurheartj/ehl388 10.1161/HYPERTENSIONAHA.109.140145 10.1159/000493805 10.3389/fphar.2016.00146 10.1016/j.bbrc.2010.12.057 10.1038/srep26131 10.1016/j.ejphar.2016.01.007 10.1152/ajpheart.00854.2014 10.1371/journal.pone.0085958 10.2337/db06‐1254 10.1042/CS20130420 10.1152/ajprenal.00516.2013 10.1161/CIRCRESAHA.109.197723 10.1016/j.bbrc.2007.05.054 10.2337/db16‐1039 10.1210/en.2008‐1274 10.1002/jcb.26440 10.1124/pr.56.4.3 10.1371/journal.ppat.1000520 10.1161/CIRCRESAHA.108.180463 10.1042/CS20130291 10.1152/ajplung.00071.2009 10.1146/annurev.cellbio.15.1.551 10.1634/stemcells.18‐4‐287 10.1073/pnas.1432869100 10.1007/s00280‐002‐0509‐4 10.1161/CIRCRESAHA.109.213140 10.2337/db12‐0808 10.1016/S0028-3908(01)00035-1 10.1016/j.febslet.2007.11.085 10.1371/journal.pone.0037649 10.1371/journal.pone.0062833 10.1007/s11010‐013‐1657‐z 10.1038/onc.2011.522 10.1016/j.molimm.2017.06.029 10.1371/journal.pone.0093965 10.1152/ajplung.90415.2008 10.1210/en.2015‐1556 10.1161/CIRCRESAHA.113.301811 |
ContentType | Journal Article |
Copyright | 2019 Wiley Periodicals, Inc. |
Copyright_xml | – notice: 2019 Wiley Periodicals, Inc. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TK 7U7 8FD C1K FR3 K9. P64 RC3 7X8 5PM |
DOI | 10.1002/jcp.28643 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts Toxicology Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Technology Research Database Toxicology Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef Genetics Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Biology |
EISSN | 1097-4652 |
EndPage | 20431 |
ExternalDocumentID | PMC6660366 30989646 10_1002_jcp_28643 JCP28643 |
Genre | article Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: National Institute on Aging funderid: AG056881 – fundername: American Heart Association funderid: 17AIREA33700012 – fundername: American Heart Association-American Stroke Association grantid: 13SDG16960025 – fundername: NIGMS NIH HHS grantid: P30 GM103332 – fundername: NIA NIH HHS grantid: R01 AG056881 |
GroupedDBID | --- -DZ -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 36B 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 9M8 A03 AAESR AAEVG AAHHS AAHQN AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDPE ABEFU ABEML ABIJN ABJNI ABPPZ ABPVW ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACNCT ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIAGR AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AUFTA AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BMXJE BNHUX BQCPF BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRSTM DU5 EBD EBS EJD EMB EMOBN F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA H.T H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ H~9 IH2 IX1 J0M JPC KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M56 MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MVM MXFUL MXSTM N04 N05 N9A NEJ NF~ NNB O66 O9- OHT OIG P2P P2W P2X P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO ROL RWI RWR RX1 RYL S10 SAMSI SUPJJ SV3 TN5 TWZ UB1 UPT V2E V8K VQP W8V W99 WBKPD WH7 WIB WIH WIK WJL WNSPC WOHZO WQJ WRC WXSBR WYB WYISQ X7M XG1 XJT XOL XPP XSW XV2 Y6R YQT YZZ ZGI ZXP ZZTAW ~IA ~WT AAYXX ADXHL AETEA AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM 7TK 7U7 8FD C1K FR3 K9. P64 RC3 7X8 5PM |
ID | FETCH-LOGICAL-c4433-c8dc5bfd05f9b85f907181e58d826686797b83f963916ee8fe655b009daece0e3 |
IEDL.DBID | DR2 |
ISSN | 0021-9541 1097-4652 |
IngestDate | Thu Aug 21 18:11:56 EDT 2025 Fri Jul 11 09:47:17 EDT 2025 Sat Jul 26 00:57:02 EDT 2025 Mon Jul 21 06:02:43 EDT 2025 Tue Jul 01 01:32:03 EDT 2025 Thu Apr 24 22:58:37 EDT 2025 Wed Jan 22 16:41:25 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | ACE2 hypoxia Mas receptor CD34+ cells |
Language | English |
License | 2019 Wiley Periodicals, Inc. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4433-c8dc5bfd05f9b85f907181e58d826686797b83f963916ee8fe655b009daece0e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Wollenzien, H. Performed research Jarajapu, YPR. Designed and supervised the study, and wrote the manuscript. Joshi, S. Performed and analyzed research Leclerc, E. Critically analyzed the data and reviewed the manuscript Author Contributions |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/6660366 |
PMID | 30989646 |
PQID | 2263162024 |
PQPubID | 1006363 |
PageCount | 12 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6660366 proquest_miscellaneous_2210255183 proquest_journals_2263162024 pubmed_primary_30989646 crossref_citationtrail_10_1002_jcp_28643 crossref_primary_10_1002_jcp_28643 wiley_primary_10_1002_jcp_28643_JCP28643 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | November 2019 |
PublicationDateYYYYMMDD | 2019-11-01 |
PublicationDate_xml | – month: 11 year: 2019 text: November 2019 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hoboken |
PublicationTitle | Journal of cellular physiology |
PublicationTitleAlternate | J Cell Physiol |
PublicationYear | 2019 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | e_1_2_9_1_14_1 e_1_2_9_1_37_1 e_1_2_9_1_15_1 e_1_2_9_1_36_1 e_1_2_9_1_12_1 e_1_2_9_1_35_1 e_1_2_9_1_13_1 e_1_2_9_1_34_1 e_1_2_9_1_10_1 e_1_2_9_1_33_1 e_1_2_9_1_11_1 e_1_2_9_1_32_1 e_1_2_9_1_31_1 e_1_2_9_1_30_1 e_1_2_9_1_2_1 e_1_2_9_1_3_1 e_1_2_9_1_4_1 e_1_2_9_1_5_1 e_1_2_9_1_6_1 e_1_2_9_1_29_1 e_1_2_9_1_27_1 e_1_2_9_1_28_1 e_1_2_9_1_25_1 e_1_2_9_1_26_1 e_1_2_9_1_23_1 e_1_2_9_1_24_1 e_1_2_9_1_21_1 e_1_2_9_1_22_1 e_1_2_9_1_42_1 e_1_2_9_1_41_1 e_1_2_9_1_40_1 Mackie A. R. (e_1_2_9_1_20_1) 2011; 38 e_1_2_9_1_7_1 e_1_2_9_1_8_1 e_1_2_9_1_9_1 e_1_2_9_1_18_1 e_1_2_9_1_19_1 e_1_2_9_1_16_1 e_1_2_9_1_39_1 e_1_2_9_1_17_1 e_1_2_9_1_38_1 |
References_xml | – ident: e_1_2_9_1_12_1 doi: 10.1167/iovs.10‐70911 – ident: e_1_2_9_1_27_1 doi: 10.1093/eurheartj/ehl388 – ident: e_1_2_9_1_7_1 doi: 10.1161/HYPERTENSIONAHA.109.140145 – ident: e_1_2_9_1_31_1 doi: 10.1159/000493805 – ident: e_1_2_9_1_40_1 doi: 10.3389/fphar.2016.00146 – ident: e_1_2_9_1_32_1 doi: 10.1016/j.bbrc.2010.12.057 – ident: e_1_2_9_1_33_1 doi: 10.1038/srep26131 – ident: e_1_2_9_1_16_1 doi: 10.1016/j.ejphar.2016.01.007 – ident: e_1_2_9_1_29_1 doi: 10.1152/ajpheart.00854.2014 – ident: e_1_2_9_1_39_1 doi: 10.1371/journal.pone.0085958 – ident: e_1_2_9_1_2_1 doi: 10.2337/db06‐1254 – ident: e_1_2_9_1_19_1 doi: 10.1042/CS20130420 – ident: e_1_2_9_1_25_1 doi: 10.1152/ajprenal.00516.2013 – ident: e_1_2_9_1_30_1 doi: 10.1161/CIRCRESAHA.109.197723 – ident: e_1_2_9_1_8_1 doi: 10.1016/j.bbrc.2007.05.054 – ident: e_1_2_9_1_34_1 doi: 10.2337/db16‐1039 – volume: 38 start-page: 474 issue: 5 year: 2011 ident: e_1_2_9_1_20_1 article-title: CD34‐positive stem cells: In the treatment of heart and vascular disease in human beings publication-title: Texas Heart Institute Journal – ident: e_1_2_9_1_17_1 doi: 10.1210/en.2008‐1274 – ident: e_1_2_9_1_3_1 doi: 10.1002/jcb.26440 – ident: e_1_2_9_1_9_1 doi: 10.1124/pr.56.4.3 – ident: e_1_2_9_1_36_1 doi: 10.1371/journal.ppat.1000520 – ident: e_1_2_9_1_42_1 doi: 10.1161/CIRCRESAHA.108.180463 – ident: e_1_2_9_1_6_1 doi: 10.1042/CS20130291 – ident: e_1_2_9_1_15_1 doi: 10.1152/ajplung.00071.2009 – ident: e_1_2_9_1_28_1 doi: 10.1146/annurev.cellbio.15.1.551 – ident: e_1_2_9_1_23_1 doi: 10.1634/stemcells.18‐4‐287 – ident: e_1_2_9_1_26_1 doi: 10.1073/pnas.1432869100 – ident: e_1_2_9_1_22_1 doi: 10.1007/s00280‐002‐0509‐4 – ident: e_1_2_9_1_13_1 doi: 10.1161/CIRCRESAHA.109.213140 – ident: e_1_2_9_1_11_1 doi: 10.2337/db12‐0808 – ident: e_1_2_9_1_10_1 doi: 10.1016/S0028-3908(01)00035-1 – ident: e_1_2_9_1_18_1 doi: 10.1016/j.febslet.2007.11.085 – ident: e_1_2_9_1_38_1 doi: 10.1371/journal.pone.0037649 – ident: e_1_2_9_1_5_1 doi: 10.1371/journal.pone.0062833 – ident: e_1_2_9_1_35_1 doi: 10.1007/s11010‐013‐1657‐z – ident: e_1_2_9_1_24_1 doi: 10.1038/onc.2011.522 – ident: e_1_2_9_1_4_1 doi: 10.1016/j.molimm.2017.06.029 – ident: e_1_2_9_1_14_1 doi: 10.1371/journal.pone.0093965 – ident: e_1_2_9_1_41_1 doi: 10.1152/ajplung.90415.2008 – ident: e_1_2_9_1_21_1 doi: 10.1210/en.2015‐1556 – ident: e_1_2_9_1_37_1 doi: 10.1161/CIRCRESAHA.113.301811 |
SSID | ssj0009933 |
Score | 2.5015583 |
Snippet | CD34+ hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells.... CD34 + hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells.... CD34 hematopoietic stem/progenitor cells (HSPCs) are vasculogenic and hypoxia is a strong stimulus for the vasoreparative functions of these cells.... |
SourceID | pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 20420 |
SubjectTerms | ACE2 Adult Aged Angiotensin AT1 receptors Angiotensin-Converting Enzyme 2 Antigens, CD34 - immunology CD34 antigen CD34+ cells Cell migration Cell proliferation Cells (biology) Enzymes Female Growth factors Hematopoietic stem cells Humans Hypoxia Hypoxia - metabolism Ischemia Leukocytes (mononuclear) Male Mas receptor Middle Aged Peptide Fragments - metabolism Peptidyl-Dipeptidase A - metabolism Plasmids Progenitor cells Proto-Oncogene Mas Proto-Oncogene Proteins - metabolism Receptors, G-Protein-Coupled - metabolism Renin-Angiotensin System - physiology Vascular endothelial growth factor Vascular Endothelial Growth Factor A - metabolism |
Title | Hypoxic regulation of angiotensin‐converting enzyme 2 and Mas receptor in human CD34+ cells |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcp.28643 https://www.ncbi.nlm.nih.gov/pubmed/30989646 https://www.proquest.com/docview/2263162024 https://www.proquest.com/docview/2210255183 https://pubmed.ncbi.nlm.nih.gov/PMC6660366 |
Volume | 234 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1baxQxFD6UguCLl9bLaJUoIgWZ7cxkMjvBp7JalkJFxEIflGFya1dtZtkLuH3yJ_gb_SWeJDNT1yqIL8NATkgmOSf5TubkOwDPcMvVMlU6NlILd3QzjN2VkphxUwqdaJMId1H46E0xPs4PT9jJBrzs7sIEfoj-wM1Zhl-vnYHXYr53SRr6SU4HWYkbKq6_LlbLAaJ3l9RRvE0j70MQWJ52rEJJttfXXN-LrgDMq3GSv-JXvwEd3IQPXddD3MnnwXIhBvLiN1bH__y2W3CjBaZkP2jSbdjQdgu29y065ecr8pz4UFF_Br8F10IGy9U2fByvps3XiSSzkNMeZ5k0htT2dNL42Hj749t3H9nu2ApOibYXq3NNMpRQ5KieYz0XV9PMyMQSny-QjF7R_AVxPxTmd-D44PX70ThuMzbEMs8pjWWpJBNGJcxwUeIDAUyZalYq9GIKx-03FCU1aPSISrUujS4YQ8PnqsbWEk3vwqZtrL4PRFCaGJ4LVqCHaJTg2i0eKlE6c5BPRLDbzV0lWzpzl1XjSxWImLMKB7HygxjB0150Gjg8_iS00ylA1ZrxvEJsStMiQxwTwZO-GA3QDUJtdbN0Mqnzy3BpjOBe0Je-FZrwkhd5EcFwTZN6AUfuvV5iJ2ee5BvdSgQXWHPXK8rfO14djt76lwf_LvoQriPw4-FO5Q5sLmZL_QjB1UI89lb0E-8_Inc |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtQwEB2VIgQvXFougQIGIVQJZZvESdaWeKm2VEvpVgi1Ul-qaJ3YZYE6q71IbJ_4BL6RL2HGuZSlICFeokgey449Y59xxmcAXuCWq_Ow0L7JtaKjm65PV0r8RBqhdKBNoOii8OAg7R_Fe8fJ8Qq8bu7CVPwQ7YEbWYZbr8nA6UB664I19FM-7kQCd9QrcJUyehNz_s6HC_IoWSeSd0EISRw2vEJBtNVWXd6NLkHMy5GSvyJYtwXt3oKTpvNV5MnnznymOvn5b7yO__t1t-FmjU3ZdqVMd2BF2zVY37bol58t2EvmokXdMfwaXKuSWC7W4aS_GJdfRzmbVGntcaJZadjQno5KFx5vf3z77oLbibDglGl7vjjTLEKJgg2GU6xHoTXlhI0scykDWW-Hx68Y_VOY3oWj3TeHvb5fJ23w8zjm3M9FkSfKFEFipBL4QAwjQp2IAh2ZlOj9ukpwg3aPwFRrYXSaJGj7shhia4Hm92DVllY_AKY4D4yMVZKik2gKJTWtH0VQ6IhQn_Jgs5m8LK8ZzSmxxpes4mKOMhzEzA2iB89b0XFF4_EnoY1GA7LakqcZwlMephFCGQ-etcVogzQIQ6vLOcmE5Jrh6ujB_Uph2lZ4IIVM49SD7pIqtQLE771cYkcfHc83epaIL7DmptOUv3c82-u9dy8P_130KVzvHw72s_23B-8ewQ3EgbK6YrkBq7PJXD9GrDVTT5xJ_QT34yaT |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1baxQxFD7UiuKLl1btaNUoIgWZ7dx3gk9l12WtthSx0IfKsLnV7SWz7AXcPvkT-hv7SzxJZqauVRBfhoGckExyTvKdzMl3AF7jlit5KKSvuGTm6KbtmyslfkpVzmQgVcDMReGd3ay_n2wfpAdL8K6-C-P4IZoDN2MZdr02Bj4SavOKNPSYj1pRjhvqDbiZZAE1eRu6n6-4o2iVR97GIKRJWNMKBdFmU3VxM7qGMK8HSv4KYO0O1LsHh3XfXeDJSWs2ZS1-_hut439-3H24WyFTsuVU6QEsSb0Cq1savfKzOXlDbKyoPYRfgVsuheV8Fb7256Py-5CTsUtqj9NMSkUG-mhY2uB4ffnjwoa2G7qCIyL1-fxMkgglBNkZTLCeCawpx2SoiU0YSDrdOHlLzB-FyUPY773_0un7VcoGnydJHPs8FzxlSgSpoizHByKYPJRpLtCNyQy5X5vlsUKrR1gqZa5klqZo-VQMsLVAxo9gWZdargFhcRwomrA0QxdRCUalWT1EIGRkMB_zYKOeu4JXfOYmrcZp4ZiYowIHsbCD6MGrRnTkSDz-JLReK0BR2fGkQHAah1mEQMaDl00xWqAZhIGW5czIhMYxw7XRg8dOX5pW4oDmNEsyD9oLmtQIGHbvxRI9_GZZvtGvRHSBNTesovy948V2Z8--PPl30Rdwe6_bKz592P34FO4gCKTufuU6LE_HM_kMgdaUPbcG9RNvtiVC |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hypoxic+Regulation+of+Angiotensin-Converting+Enzyme+2+and+Mas+Receptor+in+Human+CD34%2B+Cells&rft.jtitle=Journal+of+cellular+physiology&rft.au=Joshi%2C+Shrinidh&rft.au=Wollenzien%2C+Hannah&rft.au=Leclerc%2C+Estelle&rft.au=Jarajapu%2C+Yagna+PR&rft.date=2019-11-01&rft.issn=0021-9541&rft.eissn=1097-4652&rft.volume=234&rft.issue=11&rft.spage=20420&rft.epage=20431&rft_id=info:doi/10.1002%2Fjcp.28643&rft_id=info%3Apmid%2F30989646&rft.externalDocID=PMC6660366 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9541&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9541&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9541&client=summon |